{"nct_id":"NCT01287039","title":"A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma","status":"COMPLETED","status_verified_date":"2021-11","start_date":"2011-04","start_date_type":null,"primary_completion_date":"2013-12","primary_completion_date_type":"ACTUAL","completion_date":"2014-03","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["TEVA"]}